RecruitingPHASE2, PHASE3NCT06581406
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Studying Uveal melanoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Replimune Inc.
- Principal Investigator
- Rahul Marpadga, MD MPHReplimune Inc.
- Intervention
- RP2(biological)
- Enrollment
- 280 enrolled
- Eligibility
- All sexes
- Timeline
- 2024 – 2031
Study locations (30)
- HonorHealth Research Insisute, Scottsdale, Arizona, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- The Angeles Clinic and Research Institute, Los Angeles, California, United States
- University of California Los Angeles, Los Angeles, California, United States
- Stanford Cancer Institute, Palo Alto, California, United States
- University of Colorado Hospital - Anschutz Cancer Pavilion(ACP), Aurora, Colorado, United States
- The Melanoma & Skin Cancer Institute, Englewood, Colorado, United States
- Georgetown University Medical Center, Washington D.C., District of Columbia, United States
- Mayo Clinic - Jacksonville FL, Jacksonville, Florida, United States
- Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- Emory Winship Cancer Institute, Atlanta, Georgia, United States
- Northwestern Memorial Hospital, Chicago, Illinois, United States
- University of Chicago Medical Center, Chicago, Illinois, United States
- University of Iowa, Iowa City, Iowa, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06581406 on ClinicalTrials.govOther trials for Uveal melanoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07364474Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the LiverMassachusetts General Hospital
- RECRUITINGPHASE3NCT07015190Neoadjuvant Darovasertib in Primary Uveal MelanomaIDEAYA Biosciences
- RECRUITINGPHASE2NCT07276386Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal MelanomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGPHASE1, PHASE2NCT06961357Clinical Trial of CD40L-augmented TIL for Patients With Advanced MelanomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGPHASE1NCT07203391Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell HomeostasisSt Vincent's Hospital, Sydney
- RECRUITINGPHASE1NCT07076550A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic MelanomaAlpha-9 Oncology USA Inc.
- RECRUITINGNCT07421739Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) SubjectsAura Biosciences
- RECRUITINGPHASE1, PHASE2NCT06626516Tebentafusp-tebn With LDT in Metastatic UMThomas Jefferson University